Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)

Volume 15, 3 Issues, 2015

Download PDF Flyer

Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Garry X. Shen
University of Manitoba
Winnipeg, MB

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention

Author(s): Mustafa Yildiz, Banu Sahin Yildiz, Mustafa Ozan Gursoy and Ibrahim Akin

Affiliation: Cardiologist, Internal medicine Specialist and Physiologist, Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.


Antiplatelet therapy plays an important role in the treatment of patients suffering from acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) in order to prevent atherothrombotic events and restenosis or ischemic reocclusion, respectively. Moreover, stent implantation is often performed along with PCI to ensure that the arteries remain open. However, stent thrombosis ST is a possible complication which can occur up to about one year after the procedure. Therefore, it is standard to treat patients with a dual antiplatelet regime whereby aspirin is combined with either clopidogrel, prasugrel or ticagrelor. This review summarizes the characteristics of these P2Y12 antagonists and evaluates the current and future clinical guidelines for antiplatelet therapy in the setting of PCI with or without stenting.

Keywords: Clopidogrel, drug-eluting stent, prasugre, stent thrombosis, ticagrelor.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 14
Issue Number: 3
First Page: 225
Last Page: 230
Page Count: 6
DOI: 10.2174/1871529X14666140823142031

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science